 |
6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-bensoxazin-4-one |
|---|---|
| Trade Name | |
| Orphan Indication | Netherton syndrome |
| USA Market Approval | USA |
| USA Designation Date | 2015-06-18 00:00:00 |
| Sponsor | Sixera Pharma AB;Erik Dahlbergsgaten 11a2t, Vastra Gotaland 41126; |
